Zobrazeno 1 - 10
of 330
pro vyhledávání: '"S Riestra"'
Autor:
M Chaparro, M García Donday, S Riestra, A J Lucendo, J M Benítez, M Navarro-Llavat, J Barrio, V J Morales-Alvarado, M Rivero, D Busquets, E Leo Carnerero, O Merino Ochoa, O Nantes Castillejo, P Navarro, M Van Domselaar, A Gutiérrez Casbas, I Alonso-Abreu, R Mejuto, L Fernández Salazar, M Iborra, M D Martín-Arranz, J R Pineda, M J Sampedro, K Serra Nilsson, A Bouhmidi Assakali, L Batista, C Muñoz Villafranca, I Rodríguez-Lago, D S Ceballos Santos, I Guerra, M Mañosa, I Marín Jimenez, I Vera Mendoza, M Barreiro-de Acosta, E Domènech, M Esteve, V García-Sánchez, P Nos, J Panés, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i50-i54
Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven in clinical trials including patients in clinical, endoscopic, and radiologic remission at the time of anti-TNF withdrawal to make r
Autor:
M Baldan-Martin, M Azkargorta, I Lloro, I Soleto Fernández, M Orejudo, C Ramírez, S García, J Mercado, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández-Salazar, D Ceballos, J M Benítez, M Aguas, I Bastón-Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, V Royo, M Esteve, F Elortza, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i268-i271
Background Inflammatory bowel diseases (IBD) are chronic, heterogeneous, and inflammatory conditions mainly affecting the gastrointestinal tract. Currently, endoscopy is the gold standard test for assessing mucosal activity and healing in clinical pr
Autor:
D Muiño, L Carballo-Folgoso, J Ortega-Carriedo, P Flórez-Díez, R de Francisco, I Pérez-Martínez, A Castaño-García, E Fernández-González, C García-Pérez, S Martínez-González, V Rolle, S Riestra
Publikováno v:
Journal of Crohn's and Colitis. 17:i303-i305
Background Immune-mediated inflammatory diseases (IMIDs) involve an increased risk of developing atherosclerotic cardiovascular disease (ASCVD). However, the association between inflammatory bowel disease (IBD) and ASCVD is not well established. Our
Autor:
C Rubín De Célix, J Martín de Carpi, G Pujol, L Palomino, M Velasco, R Martín-Masot, V M Navas-López, E Ricart, M J Casanova, A Rodríguez Martínez, E Leo, A Alcaraz, M Mañosa, V Hernández, R Fernández, C Sánchez, L Menchén, F Mesonero, M Barreiro-De Acosta, N Martinon, C Tejido Sandoval, A Rendo Vázquez, P Corsino, R Vicente, A Hernández-Camba, J R Alberto Alonso, I Alonso-Abreu, A M Castro Millán, L Peries Reverter, B Castro, E Fernández-Salgado, M M Busto Cuiñas, J M Benítez, L Madero, F Clemente, S Riestra, S Jiménez-Treviño, M Boscá, M Chaparro, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i37-i39
Background It has been suggested that the transition of patients from paediatric to adult care units may be key in the outcomes of inflammatory bowel disease (IBD). However, the impact of transition in real clinical practice has been barely studied.
Autor:
I Soleto, M Baldan, C Ramírez, M Orejudo, S García, J Mercado, M Azkargorta, I Lloro, L Ortega Moreno, L Aldars Garcia, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández, D Ceballos, J M Benítez, M Aguas, I Bastón Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, D Ginard, M Esteve, F Elortza, J P Gisbert, N Martin-Cofreces, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i217-i219
Background The etiology and pathogenesis of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are complex and the mechanisms that lead to the development of these diseases remain unclear. Extracellular vesicles (EVs)
Autor:
R M De Francisco Garcia, I Pérez-Martínez, A Castaño-García, M Celada-Sendino, E Fernández-González, C García-Pérez, S Martínez-Gozález, V Rolle, R Queiro, S Alonso-Castro, J Santos-Juanes, M Gueimonde, S Riestra
Publikováno v:
Journal of Crohn's and Colitis. 17:i981-i983
Background The association of several immune-mediated inflammatory diseases (IMIDs) in the same patient is well known. IMID, especially joint and cutaneous diseases, are frequently diagnosed in patients with inflammatory bowel disease (IBD). However,
Autor:
M Baldan-Martin, I Lloro, M Azkargorta, C Ramírez, I Soleto Fernández, M Orejudo, S García, J Mercado, C H Gordillo, S Riestra, M Rivero, A Gutiérrez, I Rodríguez-Lago, L Fernández-Salazar, D Ceballos, J M Benítez, M Aguas, I Bastón-Rey, F Bermejo, M J Casanova, R Lorente, Y Ber, V Royo, M Esteve, F Elortza, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i202-i204
Background Inflammatory bowel disease (IBD) is a complex multi-factorial disease characterized by chronic inflammation of the gastrointestinal tract. Despite significant efforts to understand the pathogenetic mechanisms of IBD, the elucidation of its
Autor:
M J García, S Riestra, A Amiot, M Julsgaard, I García de la Filia, M Calafat, M Aguas, L de la Peña, C Roig-Ramos, B Caballol, M J Casanova, K Farkas, T Boysen, L Bujanda, C Cuarán, D Dobru, F Fousekis, C J Gargallo-Puyuelo, E Savarino, X Calvet, J M Huguet, L Kupcinskas, J López-Cardona, T Raine, J van Oostrom, J P Gisbert, M Chaparro
Publikováno v:
Journal of Crohn's and Colitis. 17:i911-i912
Background The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis (ASUC) to avoid colectomy and change the natural history of the disease. The effectiveness and safet
Autor:
J Llaó, E Martín-Arranz, Y Zabana, M Navarro-Llavat, E Garcia-Planella, D Busquets, D Monfort, J R Pineda, A Gutiérrez, A Villoria, L Menchén, G Bastida, F J García-Alonso, M Rivero, M Chaparro, S Riestra, O Merino, I Rodríguez-Lago, M Barreiro-de-Acosta, E Domènech Moral
Publikováno v:
Journal of Crohn's and Colitis. 17:i755-i756
Background Oral corticosteroids remain as the first-line treatment for moderately active ulcerative colitis (UC). In controlled studies, they achieved clinical remission in 30-60% of patients at 30 days. In severe systemic diseases, intravenous bolus
Autor:
M Gonzalez Vivo, M Urpí Ferreruela, B Castro Senosiain, I Pérez-Martínez, J Barrio, L Codesido Prado, B Caballol Oliva, V Pedrera Roman, M Piqueras Cano, F Rodríguez Moranta, M J Casanova González, L Ramos, M Iborra, C Tardillo Marin, M Barreiro-de Acosta, R H Lorente Poyatos, B Orts Jorquera, L Bujanda Fernández, Y Zabana, A López-García, S Riestra, P Vega-Villaamil, M Montoro, J P Gisbert, P Nos, G E Rodriguez Gonzalez, M Porto Silva, A Gutiérrez-Casbas, E Domenech, L Márquez
Publikováno v:
Journal of Crohn's and Colitis. 16:i208-i210
Background Patients with inflammatory bowel disease (IBD) are often classified as ulcerative colitis (UC) and Crohn’s disease (CD). However, in some cases this categorization is not possible and these patients are labelled as inflammatory bowel dis